Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

to placebo or teriflunomide, 7mg or 14mg, once daily. The primary endpoint was annualized relapse rate defined as the number of confirmed relapses per patients-year. The key secondary endpoint was the time to disability progression measured by EDSS. Safety and tolerability evaluations were based on treatment emergent adverse events, physical examinations, vital signs and laboratory investigations.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, unpredictable and progressively disabling disease. Patients with MS typically are diagnosed at a young age and they face a lifetime of uncertainty with gradually declining health. Today, over two million people around the world suffer from MS. MS is the result of damage to myelin, a protective sheath surrounding nerve fibres of the central nervous system. When myelin is damaged, this interferes with messages between the brain and other parts of the body. Multiple sclerosis is a very variable condition and the symptoms depend on which areas of the central nervous system have been affected. There is no definite pattern to MS and everyone with MS has a different set of symptoms, which vary from time to time and can change in severity and duration, even in the same person. Management of MS is complex; early intervention in the pathological process is recommended in order to delay disease progression or at least, slow it down. A complex support system is required for the care of MS patients, including health and social services, as well as various healthcare professionals. Although there is no known cure for multiple sclerosis, several therapies are proven to be helpful but there remains an unmet need for new oral therapies with an acceptable benefit/risk profile.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 The new research ... (High & Medium), Sub-type (Primary & Secondary), and ... & Transportation & Power Generation) - Trends and ... market with analysis and forecasting of the market ... Tables with 52 Figures spread through 146 Pages ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... (OTCQB: GNBT) today announced two presentations demonstrating that ... its novel proprietary cancer immunotherapeutic AE37 vaccine correlated ... patients. The AE37 cancer vaccine is being developed ... ( www.antigenexpress.com ). The presentations are being made ...
(Date:10/27/2014)... 27, 2014 The “Molecular Diagnostic ... Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User ... Software) - Global Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
(Date:10/27/2014)... 27, 2014 Called the NOAH ... eliminating several types of pediatric brain cancer. The ... in over 30 years of research and development. ... proves that one mom's determination can make a ... Halloween trick-or-treating, and it’s only fitting that we’ve ...
Breaking Biology Technology:Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3
... Calif., Feb. 17 Avantis Medical Systems, Inc., a ... announced today that it has received a new 510(k) ... the claim for increased detection of cancerous and pre-cancerous ... technology that has been cleared by the FDA to ...
... as Senior Scientist , BURLINGTON, Mass., ... expansion of its executive team with the appointment ... The company also announced the addition of Richard ... )The appointments reflect the evolution of the company,s ...
... LIMMERICK, Ireland, Feb. 16 Copan Innovation Ltd., whose ... collection and transport systems in the world, has named ... Development in the Pacific Rim, as well as appointed ... Innovation Ltd. Bob Cooper, who brings a background of ...
Cached Biology Technology:Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 2Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 3Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 4CorNova(R) Expands Management Team with Appointment of Robert Gallahue as Chief Financial Officer 2Copan Announces the Appointment of Bob Cooper as Vice President of Business Development in the Pacific Rim 2
(Date:10/29/2014)... of kidney cancer patients in Europe sheds light on ... an apparent link between exposure to aristolochic acid and ... research, by an international team led by scientists from ... Montreal, underscores the importance of investigating possible sources of ... of the Aristolochia genus, also has been suspected of ...
(Date:10/28/2014)... German . , ... food when times are lean? By studying wild chimpanzees ... of the Max Planck Institute for Evolutionary Anthropology in ... apes can acquire extra energy needed to maintain large, ... nests more en route to breakfast sites containing fruits ...
(Date:10/28/2014)... of Health (NIH) announced awards to expand the ... National Center for Advancing Translational Sciences (ORDR-NCATS) collaborative ... the network, physician scientists at 22 consortia will ... clinical research and investigate new treatments for patients ... by $29 million in fiscal 2014 funding from ...
Breaking Biology News(10 mins):Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3The early chimp gets the fig 2The early chimp gets the fig 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... IN Traditional turfgrass management programs rely heavily ... In response to increased public scrutiny and legislation, ... but research indicates that these alternatives have not ... lawn care industry. Results of a new study ...
... as the great pandemia of the XXI century. Recent data ... suffering from overweight, of which 300 million are clinically obese. ... worrying increase, with more than 155 million children and adolescents ... Biologist Aline Jelenkovic analysed to what point corporal morphology was ...
... QUEBEC, CANADA A study in HortTechnology ... reducing solar heat radiation and temperatures during the hot ... Canadian researchers, was the first investigation into the effects ... shading method. Results showed that the technology improved greenhouse ...
Cached Biology News:Turfgrass fertility, pesticide programs compared 2The amount of adipose tissue should be taken into account in the fight against obesity 2The amount of adipose tissue should be taken into account in the fight against obesity 3New technology improves greenhouse, plant microclimates 2
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
muscle actin (HUC1-1)...
... Neural Stem Cell Functional Identification Kit ... can be used for the short-term ... and the induction of NSCs into ... antibody panel consisting of mouse anti-human ...
Biology Products: